Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study

Zhimin Shao; Zhongsheng Tong; Qiang Liu; Wei Li; Li Cai; Kunwei Shen; Huiping Li; Chuan Wang; Jin Yang; Zhenchuan Song; Shui Wang; Ting Luo; Wenhe Zhao; Haibo Wang; Yueyin Pan; Jianyun Nie; Xiaohua Zeng; Yanqing Bai; Wendy Chiang; Valeria Guarnaccia; Yu Bi; Binghe Xu

doi:10.1002/cam4.7408

Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study

Zhimin Shao
, Zhongsheng Tong
, Qiang Liu
, Wei Li
, Li Cai
, Kunwei Shen
, Huiping Li
, Chuan Wang
, Jin Yang
, Zhenchuan Song
, Shui Wang
, Ting Luo
, Wenhe Zhao
, Haibo Wang
, Yueyin Pan
, Jianyun Nie
, Xiaohua Zeng
, Yanqing Bai
, Wendy Chiang
, Valeria Guarnaccia

Yu Bi, Binghe Xu

Research output: Contribution to journal › Article › peer-review

1 Scopus citations

Original language	English
Article number	e7408
Journal	Cancer Medicine
Volume	13
Issue number	15
DOIs	https://doi.org/10.1002/cam4.7408
State	Published - Aug 2024
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1002/cam4.7408

Cite this

Shao, Z., Tong, Z., Liu, Q., Li, W., Cai, L., Shen, K., Li, H., Wang, C., Yang, J., Song, Z., Wang, S., Luo, T., Zhao, W., Wang, H., Pan, Y., Nie, J., Zeng, X., Bai, Y., Chiang, W., ... Xu, B. (2024). Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study. Cancer Medicine, 13(15), Article e7408. https://doi.org/10.1002/cam4.7408

@article{d5dc1ab3aa5b47f3bfe96c2480c3d69d,

title = "Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study",

author = "Zhimin Shao and Zhongsheng Tong and Qiang Liu and Wei Li and Li Cai and Kunwei Shen and Huiping Li and Chuan Wang and Jin Yang and Zhenchuan Song and Shui Wang and Ting Luo and Wenhe Zhao and Haibo Wang and Yueyin Pan and Jianyun Nie and Xiaohua Zeng and Yanqing Bai and Wendy Chiang and Valeria Guarnaccia and Yu Bi and Binghe Xu",

year = "2024",

month = aug,

doi = "10.1002/cam4.7408",

language = "英语",

volume = "13",

journal = "Cancer Medicine",

issn = "2045-7634",

publisher = "John Wiley and Sons Inc",

number = "15",

}

Shao, Z, Tong, Z, Liu, Q, Li, W, Cai, L, Shen, K, Li, H, Wang, C, Yang, J, Song, Z, Wang, S, Luo, T, Zhao, W, Wang, H, Pan, Y, Nie, J, Zeng, X, Bai, Y, Chiang, W, Guarnaccia, V, Bi, Y & Xu, B 2024, 'Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study', Cancer Medicine, vol. 13, no. 15, e7408. https://doi.org/10.1002/cam4.7408

TY - JOUR

T1 - Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre- and postmenopausal Chinese women

T2 - Primary results from a phase 2 randomized study

AU - Shao, Zhimin

AU - Tong, Zhongsheng

AU - Liu, Qiang

AU - Li, Wei

AU - Cai, Li

AU - Shen, Kunwei

AU - Li, Huiping

AU - Wang, Chuan

AU - Yang, Jin

AU - Song, Zhenchuan

AU - Wang, Shui

AU - Luo, Ting

AU - Zhao, Wenhe

AU - Wang, Haibo

AU - Pan, Yueyin

AU - Nie, Jianyun

AU - Zeng, Xiaohua

AU - Bai, Yanqing

AU - Chiang, Wendy

AU - Guarnaccia, Valeria

AU - Bi, Yu

AU - Xu, Binghe

PY - 2024/8

Y1 - 2024/8

UR - https://www.scopus.com/pages/publications/85201080998

U2 - 10.1002/cam4.7408

DO - 10.1002/cam4.7408

M3 - 文章

C2 - 39136200

AN - SCOPUS:85201080998

SN - 2045-7634

VL - 13

JO - Cancer Medicine

JF - Cancer Medicine

IS - 15

M1 - e7408

ER -

Initial ribociclib plus endocrine therapy for HR+/HER2− advanced breast cancer in pre- and postmenopausal Chinese women: Primary results from a phase 2 randomized study

UN SDGs

Access to Document

Other files and links

Cite this